Aaron D. Krabill

Aaron D. Krabill's research focuses on designing small-molecule drugs that target specific enzymes involved in disease, particularly protein tyrosine phosphatases (enzymes that remove phosphate groups from proteins, affecting cell signaling) and deubiquitinases (enzymes that remove ubiquitin tags used to mark proteins for degradation or regulation). Much of this work involves creating covalent inhibitors—molecules that form a permanent chemical bond with their target—as potential treatments for cancer, neurodegenerative disease, and antibiotic-resistant bacterial infections. The work combines medicinal chemistry (drug design) with biochemistry to characterize how these inhibitors work at a molecular level.

Publication output has been modest and somewhat uneven over the last decade, with a recent increase in activity in 2024-2025 following a gap in 2022.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026